{"entity":{"id":"idea-reg-comparability-by-design-digital-twin","kind":"idea","name":"Comparability by design: a digital twin and sentinel panel for cell process changes","aka":[],"tldr":"Improving how a cell therapy is made currently risks having to repeat clinical trials. A validated computer model plus a fixed set of product measurements would let changes be approved on data alone.","summary":"Because assays of how well a cell-therapy batch kills its target are imperfect, regulators often require clinical bridging when a cell-therapy process changes (new device, new site, shorter culture), freezing suboptimal processes. The proposal is a pre-agreed comparability framework: a mechanistic and statistical model of the process (a digital twin) validated against historical runs, a sentinel panel of product attributes (phenotype, transcriptomic signature, cytotoxicity, cytokine profile, vector copy number) with pre-specified equivalence margins, and a regulatory commitment to accept changes that fall within the margins without clinical data.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)","url":"https://doi.org/10.1001/jamaoncol.2018.0977"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t","single-cell-spatial"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy","b-regulatory-fragmentation"],"keyPapers":["paper-hernandez-jama-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Under the framework, the median time to implement a major cell-therapy process change falls from more than two years to under six months, with no detectable change in clinical outcomes in the outcomes registry.","rationale":"Biosimilars established that analytical similarity within margins can replace clinical trials; cell therapies need richer attribute panels, but single-cell and transcriptomic characterisation now make such panels feasible.","test":"Retrospectively apply the sentinel panel to products that underwent process changes with known clinical outcomes to calibrate margins; then pilot the framework prospectively with two manufacturers and regulators.","maturity":"speculative","actor":"regulator","cost":"medium","horizonYears":4},"route":"/ideas/idea-reg-comparability-by-design-digital-twin/","neighbours":{"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"single-cell-spatial","kind":"technology","name":"Single-cell & spatial profiling","route":"/technologies/single-cell-spatial/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/"}],"paper":[{"id":"paper-hernandez-jama-oncol","kind":"paper","name":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","route":"/key-papers/paper-hernandez-jama-oncol/"}]}}